07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

ALK-Abello, AllerQuest deal

AllerQuest granted ALK-Abello exclusive, worldwide rights to commercialize its Minor Determinant Mixture (MDM) penicillin allergy skin test. AllerQuest, which is developing MDM, is eligible up to $3.5 million in milestones from ALK-Abello. Clinical testing of...